Clinical Report: Epigenetic Factors in Bipolar Disorder: A Bibliometric Overview
Overview
This bibliometric study analyzes the evolving landscape of epigenetic research in bipolar disorder (BD), highlighting significant trends and influential contributors. Key findings indicate a shift towards understanding dynamic regulatory networks and potential biomarkers for BD.
Background
Bipolar disorder is a chronic psychiatric condition with a global prevalence of 1.5% to 2.4%, significantly impacting public health. The role of epigenetics in BD pathogenesis is gaining attention, as it may reveal novel biomarkers and therapeutic targets. Understanding these mechanisms is crucial for advancing clinical care and treatment strategies.
Data Highlights
{'format': 'Ensure the table is properly formatted in the final document.'}
Key Findings
The United States is the most productive country in epigenetic BD research.
Harvard University is identified as the leading institution in this field.
Kato T is the most prolific author, while Nöthen MM is the most highly co-cited scientist.
Molecular Psychiatry has the highest publication volume and citation frequency.
Current research focuses on histone modifications, HDAC inhibitors, and long noncoding RNAs.
There is a notable interplay between genetic variants and epigenetic regulation in BD.
Clinical Implications
The findings underscore the importance of epigenetic mechanisms in understanding bipolar disorder, which may lead to the identification of novel biomarkers for diagnosis and treatment. Clinicians should remain informed about the evolving research landscape to integrate potential epigenetic insights into future therapeutic strategies.
Conclusion
This bibliometric overview highlights the significant advancements in epigenetic research related to bipolar disorder, emphasizing the need for continued exploration of these mechanisms to enhance clinical outcomes.
